PTO/SB/08a (01-22)
`Doc code: IDS
`Approvedfor use through 05/31/2024. OMB 0651-0031
`Doc description: Information Disclosure Statement (IDS) Filed
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`First Named Inventor
`
`AmirAli TALASAZ
`
`Art Unit
`
`
`
`
`
`Examiner Name Attorney Docket Number
`
`fase
`Application Number
`Filing Date
`FeocmeSSCS
`
`
`
`
`| 42534-708.313
`
`
`[Remove]
`U.S.PATENTS
`
`Kind
`Code’ Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`
`
`
`
`
`
`
`
` Name of Patentee or
`
`
`Add
`If you wish to add additional U.S. Patent citation information please click the Add button.
`[Remove]
`U.S.PATENT APPLICATION PUBLICATIONS
`
`Pages,Columns,Lines where
`
`
`Examiner Kind|PublicationPublication
`Name of Patentee or Applicant
`Cite No
`Relevant Passages or Relevant
`Number
`Initial*
`Code’) Date
`of cited Document
`Figures Appear
`
`If you wish to add additional U.S. Published Application citation information please click the Add button]Add|
`
`FOREIGN PATENT DOCUMENTS [Remove]
`
`
`
`Pages,Columns,Lines
`
`
`
`
`Examiner] Cite Kind|Publication where Relevant
`Foreign Document
`
`Ts
`
`Code‘! Date
`Applicant of cited
`
`
`Initial*
`No
`Number?
`Passages or Relevant
`Document
`
`Figures Appear
`
`
`If you wish to add additional Foreign Patent Documentcitation information please click the Add button
`
`[Remove]
`NON-PATENT LITERATURE DOCUMENTS
`
`Include name of the author (in CAPITAL LETTERS),title of the article (when appropriate), title of the item
`Examiner) Cite
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`TS
`Initials*|No
`publisher, city and/or country where published.
`
`
`EFS Web 2.1.18
`
`

`

`
`
`
`
`Application Number 17809544
`
`
`Filing Date
`2022-06-28
`
`INFORMATION DISCLOSURE First Named Inventor|AmirAli TALASAZ
`
`STATEMENT BY APPLICANT
`Art Unit
`|
`
`
`
` Attorney Docket Number
`
`
`
`
`| 42534-708.313 iomarkers. 2010 Aug; 14{4):455-60. doi: 10.1089/gtmb.2010.0029.
`
`( Not for submission under 37 CFR 1.99)
`
`Examiner Name
`
`STITZIEL, et al. Computational and statistical approaches to analyzing variants identified byexome sequencing.
`enomeBiol. 2011 Sep 14;12(9):227. doi: 10.1186/gb-2011-12-9-227.
`
`Stroun, M, et al, "About the possible orgin and mechanism ofcirculating DNA apoptosis and active DNA release", Clin
`him Acta, vol. 313, No. 1-2, pp. 139-142, (2001).
`
`STUMM, M. et al. "Noninvasive prenatal detection of chromosomal aneuploidies using different next generation
`Bequencing strategies and algorithms” Prenatal Diagnosis (2012) 32:569-577
`
`SWANSON, A.et al. "Non-invasive prenatal testing for fetal aneuploidy by massively parallel DNA sequencing of
`atemal plasma : the future has arrived today” J Lab Med (2012) 36(5):269-275
`
`ABACK,et al. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancerpatients.
`ancer Res. 2003 Apr 15:63(8): 1884-7
`
`AN, et al. Genome-wide comparison of DNA hydroxymethylation in mouse embryonic stem cells and neural
`progenitor cells by a new comparative hMeDIP-seq method. Nucleic Acids Res. 2013 Apr,41(7):e84. doi: 10.1093/nar/
`9kt091. Epub 2013 Feb 13.
`
`AUDIEN, et al. Haplotyping and copy numberestimation of the highly polymorphic human beta-defensin locus on
`Bp23 by 454 amplicon sequencing. BMC Genomics. 2010 Apr 19:11:252. doi: 10.1186/1471-2164-11-252.
`
`EER,J.K. et al. "Systematic comparison of three genomic enrichment methods for massively parallel DNA
`Bequencing” Genome Res (2010) 20(10): 1420-1431
`
`hruPLEX{TM) DNA-seq Kit Instruction Manual, Rubicon Genomics (2014)
`
`IE, J. et al., “Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with
`Blage Il colon cancer,”Sci. Transl. Med. 2016, 8(346):346ra92
`
`OMAZ,et al. Differential methylation as a cause of allele dropout at the imprinted GNASlocus. Genet Test Mol
`
`EFS Web 2.1.18
`
`

`

`
`
`
`
`Application Number 17809544
`
` Attorney Docket Number
`
`
`
`_—_=_=~oa
`
`| 42534-708.313 'S Provisional Appl. No. 61/432119 filed 1/12/2011.
`
`
`Filing Date 2022-06-28
`INFORMATION DISCLOSURE First Named Inventor|AmirAli TALASAZ
`
`
`STATEMENT BY APPLICANT
`
`Art Unit |
`( Not for submission under 37 CFR 1.99)
`
`Examiner Name
`
`OMLINSON, et al. A genome-wide association scan of tag SNPsidentifies a susceptibility variant for colorectal
`ancer at 8q?4 21. Nat Genet. 2007 Aug;39(8) 984-8. Epub 2007 Jul 8.
`
`RAPNELL,C.et al. "How to mapbillions of short reads onto genomes" Nature Biotech (2009) 27(5):-455-457
`
`SAI, et al. Discovery of rare mutations in populations: TILLING by sequencing. Plant Physiol. 2011 Jul;156
`3):1257-68. doi: 10.1104/pp.110.169748. Epub 2011 Apr 29.
`
`winstrand Biosciences, Inc. & The University of Washington v. Guardant Health, Inc. Complaint 1-21-cv-01126, dated
`August 3, 2071
`
`S. Appn. No. 14/102,285, filed 12/10/2013
`
`.9. Provisional Application 61/613,413 (Schmitt '413 provisional”) (2012-03-20)
`
`9. Provisional Application 61/625,319 (Schmitt '319 provisional”) (2012-04-17)
`
`CSC GenomeBioinformatics. About the UCSC GenomeBioinformatics Site. http://genome.ucsc.edu/index.html.
`Accessed on 05/26/2015. 2 pgs.
`
`METANI et al. Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum. Journal of
`linical Oncology 24(26).4270-4276 (September 10, 2006).
`
`S Provisional Appl. No. 61/384001 filed 9/17/2010.
`
`—_-wNo
`
`—_
`
`NoSo
`
`ho
`
`NoNo
`
`EFS Web 2.1.18
`
`

`

`
`
`
`
`Application Number 17809544
`
`
`
`Filing Date 2022-06-28
`
`
`
`Art Unit |
`
` Attorney Docket Number
`
`
`
`
`| 42534-708.313 ELCULESCU, et al. Serial Analysis of Gene Expression. Science, 270: 484-487 (1995).
`
`INFORMATION DISCLOSURE
`First Named Inventor|AmirAli TALASAZ
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Examiner Name
`
`S Provisional Appl. No. 61/625,623filed 04/17/2012.
`
`S Provisional Application No. 61/798,925 filed 03/15/2013. ("Diehn")
`
`TTING, et al. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive
`ethod for the detection of bladder cancer. Clin Cancer Res. 2002 Jan;8(1):35-40.
`
`AN HOUTEN, et al. Mutated p53 as a molecular markerfor the diagnosis of head and neck cancer. J Pathol. 2002
`Nec; 198(4)-476-86.
`
`an Kets, V. et al. "Kapa Hyper Prep: A Next-Generation Kit for Fast and Efficient Library Construction from
`hallenging DNA Samples” Poster (2014)
`
`AN LOO, P. et al. "Allele-specific copy number analysis of tumors" PNAS (2010) 107(39}:16910-16915
`
`AN NIEUWERBURGH, F. et al. "Quantitative Bias in Illumina TruSeq and a Novel Post Amplification Barcoding
`Strategy for Multiplexed DNA and Small RNA Deep Sequencing” PLoS One (2011) with Supporting Information
`
`an Orsouw, N. et al. "Complexity Reduction of Polymorphic Sequences (CRoPSTM): A Novel Approach for Large-
`Scale Polymorphism Discovery in Complex Genomes" PLoS One (2007) 11(61172):1-10
`
`ASYUKHIN, V. et al., "K-Ras Point Mutations in the Blood Plasma DNAof Patients with Colorectal Tumors"
`hallenges of Modern Medicine, 141-150 (Verna and Shamoo eds, 1994)
`
`ELCULESCU, et al. Characterization of the Yeast Transcriptome. Cell, 88: 243-251 (1997).
`
`Now
`
`Boag
`
`Nooa
`
`wNoNoNoNo=Sowoco~ao
`
`wwwNo
`
`ww
`
`EFS Web 2.1.18
`
`

`

`
`
`
`
`Application Number 17809544
`
`
`
`Filing Date 2022-06-28
`
`
`
`Art Unit |
`
` Attorney Docket Number
`
`
`
`
`| 42534-708.313 squamous cell carcinomas,” Sci. Transl. Med. 2015, 7(293):293ra104
`
`INFORMATION DISCLOSURE
`First Named Inventor|AmirAli TALASAZ
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Examiner Name
`
`wwwa
`
`wao
`
`>awwwwoS©co~
`>>WwNo=
`
`ENNISON, S.J. "Chapter 5: Restriction Digestion and Ligation of DNA" in Laboratory Manual for Genetic Engineering
`2009) Easter Economy Edition, PHI Learning Private Limited” pp. 32-35
`
`OGELSTEIN, etal. Digital PCR. Proc. Natl. Acad. Sci., 96(16): 9236-924 1(1999).
`
`'AGLE,N. et al., “High-throughput Detection of actionable Genomicalterationsin clinical tumor samples by targeted,
`assively Parallel sequencing,” Cancer Discov. 2012, (2)1:82-93
`
`ALKER,et al. Isothermalin vitro amplification of DNA by a restriction enzyme/DNA polymerase system. Proc Natl
`Acad Sci US A. 1992 Jan 1;89(1):392-6.
`
`ALSH, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively
`parallel sequencing. Proc Natl Acad Sci U $ A. 2010 Jul 13;107(28)-12629-33. doi: 10.1073/pnas.1007983107. Epub
`PO10 Jun 28.
`
`ANG, et al. iCLIP predicts the dual splicing effects of TIA-RNA interactions, 2010 Oct, PLoS Bicol, 8(10):e1000530.
`
`ANG, et al. Molecular detection of APC, K- ras, and p53 mutationsin the serum of colorectal cancer patients as
`irculating biomarkers. World J Surg. 2004 Jul;28(7)}: 721-6. Epub 2004 Jun 8
`
`ANG, et al. RNA-Seq: a revolutionary tool for transcriptomics. Nature Reviews Genetics, 10: 57-63 (2009).
`
`ANG, T.L. et al. "Digital Karyotyping” PNAS (2002) 99(25):16156-16161
`
`ANG, T.T. et al. "High efficiency error suppression for accurate detection of low-frequency variants" NAR (2019) 47
`15):
`
`ihBK
`
`ANG, Y. et al., “Detection of somatic mutations and HPVin the saliva and plasmaofpatients with head and neck
`
`EFS Web 2.1.18
`
`

`

`
`
`Application Number 17809544
`
`
`Filing Date 2022-06-28
`
`INFORMATION DISCLOSURE First Named Inventor|AmirAli TALASAZ
`STATEMENT BY APPLICANT
`|...
`
`
`
`( Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`
`Examiner Name
`
`Attorney Docket Number
`
`| 42534-708.313
`
`
`
`ANG, Y. et al., “Detection of tumor-derived DNAin cerebrospinalfluid of patients with primary tumors of the brain
`And spinal cord,” Proc. Natl. Acad. Sci. USA 2015, 112(31), 9704-9709
`
`ANG, Y. et al., “Diagnostic potential of tumor DNA from ovarian cystfluid,” eLife 2016, 5:e15175
`
`EBER, et al.A real-time polymerase chain reaction assay for quantification of allele ratios and correction of
`Amplification bias. Anal Biochem. 2003 Sep 15:320(2}):252-8.
`
`HEELER,D.A.et al., “The complete genomeof an individual by massively parallel DNA sequencing,” Nature 2008,
`H52(7 189), 872-876
`
`ILLIFORD, A.et al., “Gene Fusion,” eLS 2013, 1-8
`
`ITTES, et al. Searching for Evidence of Altered Gene Expression: a CommentonStatistical Analysis of Microarray
`Data. Journal of the National CancerInstitute, 91(5): 400-401 (1999).
`
`If you wish to add additional non-patentliterature documentcitation information please click the Add button
`
`EXAMINER SIGNATURE
`
`*EXAMINER:Initial if reference considered, whetheror not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP $01.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST.3). > For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial numberof the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicantis to place a check mark here if
`English language translation is attached.
`
`EFS Web 2.1.18
`
`

`

`
`
`Application Number 17809544
`
`Filing Date 2022-06-28
`
`INFORMATION DISCLOSURE First Named Inventor|AmirAli TALASAZ
`
`STATEMENT BY APPLICANT
`|...
`
` Attorney Docket Number
`
`
`Examiner Name
`
`| 42534-708.313
`
`
`
`
`
`( Not for submission under 37 CFR 1.99)
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection{s):
`
`CERTIFICATION STATEMENT
`
`That each item of information contained in the information disclosure statement was first cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1).
`
`OR
`
`[-]
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
`any individual designated in 37 CFR 1.56(c) more than three monthsprior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`
`See attachedcertification statement.
`
`The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`* Acertification statement is not submitted herewith.
`
`SIGNATURE
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`Signature
`
` Name/Print
`
`2022-08-12
`
`
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public whichis to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you
`require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionerfor Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`EFS Web 2.1.18
`
`

`

`Privacy Act Statement
`
`attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised
`that:
`(1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited
`is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to
`process and/or examine your submission related to a patent application or patent.
`If you do not furnish the requested
`information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonmentof the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
`(5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
`Departmentof Justice to determine whether the Freedom ofInformation Act requires disclosure of these record s.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence toa
`court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
`negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`requestinvolving an individual, to whom the record pertains, when the individual has requested assistance from the
`Memberwith respect to the subject matter of the record.
`
`
`
` The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for
`the information in order to perform a contract. Recipients of information shall be required to comply with the
`requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
`may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
`to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of
`National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or
`his/her designee, during an inspection of records conducted by GSAaspart of that agency's responsibility to
`recommend improvements in records management practices and programs, underauthority of 44 U.S.C. 2904 and
`2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant(i.e., GSA or Commerce)directive. Such disclosure shall not be used to make
`determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record
`may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record wasfiled in
`an application which became abandonedor in which the proceedings were terminated and which application is
`referenced by either a published application, an application open to public inspections or an issued patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency,if the USPTO becomes aware ofa violation or potential violation of law or regulation.
`
`
`
`EFS Web 2.1.18
`
`